Type 2 diabetes mellitus (DM2) − a disorder of carbohydrate metabolism caused by predominant insulin resistance and relative insulin deficiency, or a predominant defect in insulin secretion with insulin resistance.
Diabetes mellitus has been defined by the World Health Organization (WHO) as a non-communicable epidemic and, in this regard, in 2006, the United Nations (UN) resolution on the fight against this disease was adopted.
This is the fourth resolution on diseases in the history of the UN, the first three were devoted to the fight against malaria, tuberculosis, HIV infection.
Find out in the article on estet-portal.com which modern drugs can significantly simplify the task of treating type 2 diabetes and minimize complications in this disease.
- World diabetes epidemic
- Research into a new group of drugs for the treatment of type 2 diabetes
- Evidence for the effectiveness of empagliflozin in the treatment of type 2 diabetesa
World Diabetes Epidemic
In the early 80s, the number of patients with diabetes mellitus (DM) was about 30 million, today it is already more than 366 million, and according to experts International Diabetes Federation (International Diabetes Federation) and WHO, more than 552 million patients are expected by 2030.
Follow us on Instagram!
The number of patients with type 2 diabetes is growing in all countries of the world without exception, most often among people aged 40-59 years, and in 183 million people DM remains undiagnosed.
Foot ulcer in diabetes mellitus: rational antibiotic therapy
Type 2 diabetes has an increased risk of developing cardiovascular complications such as:
- ischemic heart disease;
- myocardial infarction;
- arterial hypertension;
- acute cerebrovascular accident;
- chronic kidney disease.
Metabolic disorders entail the development and progression of cardiovascular diseases, as well as cardiovascular risk, since the existing approaches to normalizing glucose levels have not led to a noticeable effect on reducing the frequency of complications y.
Sodium glucose cotransporter type 2 (iSGLT2) inhibitors are a new class of antidiabetic drugs that improve glycemic control through insulin-independent mechanisms of action that are associated with increased urinary glucose secretion.
Research on a new group of drugs for the treatment of type 2 diabetes
In a retrospective analysis of the study EMPA-REG OUTCOME, which included adult patients with diabetes type 2 diabetes and confirmed cardiovascular disease, evaluated the beneficial effect of empagliflozin on the cardiovascular system.
Analysis showed that empagliflozin has a significant stabilizing effect in cardiovascular disease (reduction of cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes mellitus and CVD) based on cardiovascular risk factors, which include:
- blood glucose level;
- cholesterol levels or statin use;
- blood pressure levels and taking blood pressure medications;
- presence of albumin in urine;
- taking acetylsalicylic acid;
- tobacco smokinge.
Hyperglycemia and myocardial infarction: is there a link
Confirmation of the effectiveness of empagliflozin in the treatment of type 2 diabetes
The use of empagliflozin in a clinical study on its effectiveness in the treatment of type 2 diabetes mellitus and cardiovascular complications resulted in the following results:
- 38% reduction in risk of cardiovascular mortality;
- 35% reduction in risk of hospitalization for heart failure;
- 14% reduction in risk of 3P-MACE (CVD death, non-fatal heart attack or stroke)
Scientists recommend the use of drugs with proven efficacy to reduce the risk of cardiovascular disease in patients with type 2 diabetes.
Updated versions of more than 60 recommendations worldwide now include the results of this study as evidence for the control and stabilization of cardiovascular disease and complications with empagliflozin in the treatment of patients with type 2 diabetes.
Share:
Add a comment